50 pairs per box, 4 boxes per carton
Buy direct from Mun
Aegis, like an armour, offers superb hand barrier protection and chemical resistance. Our recommended sterile glove is thicker, with an extended cuff to suit situations which require greater protection.
Features
| Reorder code | Size |
|---|---|
| SNT154SS | Small |
| SNT154MM | Mediume |
| SNT154LL | Large |
| SNT154XL | X-Large |
| Glove Properties | Measurement (mm) |
|---|---|
| Length | ≥280 |
| Thickness at Palm (centre of Palm) | 0.09 ± 0.02 |
| Thickness at Finger (13mm ± 3mm from tip) | 0.14 ± 0.02 |
| Physical Properties | Before Ageing | After Ageing |
|---|---|---|
| Tensile Strength (MPa) | ≥18 | ≥16 |
| Elongation (%) | ≥500 | ≥400 |
| Inspection Levels and AQL | Inspection Level | AQL |
|---|---|---|
| Watertightness | G1 | 1.5 |
| Physical Dimensions | S2 | 4.0 |
| Tensile Strength | S2 | 4.0 |
| Visual Inspection (Major) | S4 | 2.5 |
| Visual Inspection (Minor) | S4 | 4.0 |
| Particulate Residue | N=5 | ≤2mg/glove |
| Packaging | |
|---|---|
| Configuration | 1 pair per pouch 50 pairs per box 4 boxes per carton |
| Regulatory Compliance | |
|---|---|
| Regulations | ARTG 203002 FDA 510(k) MDD 93/42/EEC REACH ROHS Directive 2002/95/EC EU 10/2011 EC 1935/2004 EU 2016/425 |
| International Standards | |
|---|---|
| Standards | ISO 11193-1 ASTM D5151 ASTM D6319 ASTM D6124 ASTM D6978 EN ISO 374 part 1 (Type B), 2, 4 & 5 EN 16523-1 EN 455 part 1, 2 & 3 EN 1186 EN 13130 CEN/TS 14234 ISO 10993 part 5 & 10 HACCP International Certified |
| Manufacturing Accreditations | |
|---|---|
| Accreditations | ISO 9001 ISO 13485 EN ISO 13485 |
| Chemotherapy Drugs and Concentration (Tested for Resistance to Permeation by Chemotherapy Drugs as per ASTM D6978-05, Test Report PN 138022) | Minimum Breakthrough Detection Time (minutes) |
|---|---|
| Carmustine (BCNU), 3.3mg/ml (3,300ppm) | 43.8 |
| Cisplatin, 1.0mg/ml (1,000ppm) | >240 |
| Cyclophosphamide (Cytoxan), 20.0mg/ml (20,000ppm) | >240 |
| Dacarbazine (DTIC), 10.0mg/ml (10,000ppm) | >240 |
| Doxorubicin Hydrochloride, 2.0mg/ml (2,000ppm) | >240 |
| Etoposide (Toposar), 20.0mg/ml (20,000ppm) | >240 |
| Fluorouracil, 50.0mg/ml (50,000ppm) | >240 |
| Methotrexate, 25.0mg/ml (25,000ppm) | >240 |
| Mitomycin C, 0.5mg/ml (500ppm) | >240 |
| Paclitaxel (Taxol), 6.0mg/ml (6,000ppm) | >240 |
| Thiotepa, 10.0mg/ml (10,000ppm) | 97.8 |
| Vincristine Sulfate, 1.0mg/ml (1,000ppm) | >240 |
| WARNING: Carmustine and Thiotepa, at the tested concentration, degraded an Aegis sterile nitrile glove at 43.8 minutes and 97.8 minutes respectively. The safe use of gloves in chemotherapy treatment is solely the decision of clinicians authorised to make such a decision. | |
| Reorder code | Size |
|---|---|
| SNT154SS | Small |
| SNT154MM | Mediume |
| SNT154LL | Large |
| SNT154XL | X-Large |
| Glove Properties | Measurement (mm) |
|---|---|
| Length | ≥280 |
| Thickness at Palm (centre of Palm) | 0.09 ± 0.02 |
| Thickness at Finger (13mm ± 3mm from tip) | 0.14 ± 0.02 |
| Physical Properties | Before Ageing | After Ageing |
|---|---|---|
| Tensile Strength (MPa) | ≥18 | ≥16 |
| Elongation (%) | ≥500 | ≥400 |
| Inspection Levels and AQL | Inspection Level | AQL |
|---|---|---|
| Watertightness | G1 | 1.5 |
| Physical Dimensions | S2 | 4.0 |
| Tensile Strength | S2 | 4.0 |
| Visual Inspection (Major) | S4 | 2.5 |
| Visual Inspection (Minor) | S4 | 4.0 |
| Particulate Residue | N=5 | ≤2mg/glove |
| Packaging | |
|---|---|
| Configuration | 1 pair per pouch 50 pairs per box 4 boxes per carton |
| Regulatory Compliance | |
|---|---|
| Regulations | ARTG 203002 FDA 510(k) MDD 93/42/EEC REACH ROHS Directive 2002/95/EC EU 10/2011 EC 1935/2004 EU 2016/425 |
| International Standards | |
|---|---|
| Standards | ISO 11193-1 ASTM D5151 ASTM D6319 ASTM D6124 ASTM D6978 EN ISO 374 part 1 (Type B), 2, 4 & 5 EN 16523-1 EN 455 part 1, 2 & 3 EN 1186 EN 13130 CEN/TS 14234 ISO 10993 part 5 & 10 HACCP International Certified |
| Manufacturing Accreditations | |
|---|---|
| Accreditations | ISO 9001 ISO 13485 EN ISO 13485 |
| Chemotherapy Drugs and Concentration (Tested for Resistance to Permeation by Chemotherapy Drugs as per ASTM D6978-05, Test Report PN 138022) | Minimum Breakthrough Detection Time (minutes) |
|---|---|
| Carmustine (BCNU), 3.3mg/ml (3,300ppm) | 43.8 |
| Cisplatin, 1.0mg/ml (1,000ppm) | >240 |
| Cyclophosphamide (Cytoxan), 20.0mg/ml (20,000ppm) | >240 |
| Dacarbazine (DTIC), 10.0mg/ml (10,000ppm) | >240 |
| Doxorubicin Hydrochloride, 2.0mg/ml (2,000ppm) | >240 |
| Etoposide (Toposar), 20.0mg/ml (20,000ppm) | >240 |
| Fluorouracil, 50.0mg/ml (50,000ppm) | >240 |
| Methotrexate, 25.0mg/ml (25,000ppm) | >240 |
| Mitomycin C, 0.5mg/ml (500ppm) | >240 |
| Paclitaxel (Taxol), 6.0mg/ml (6,000ppm) | >240 |
| Thiotepa, 10.0mg/ml (10,000ppm) | 97.8 |
| Vincristine Sulfate, 1.0mg/ml (1,000ppm) | >240 |
| WARNING: Carmustine and Thiotepa, at the tested concentration, degraded an Aegis sterile nitrile glove at 43.8 minutes and 97.8 minutes respectively. The safe use of gloves in chemotherapy treatment is solely the decision of clinicians authorised to make such a decision. | |
